Who Is a Good Candidate for Stem Cell Therapy?

One of the most important questions a regenerative medicine physician must answer before recommending any treatment is whether a specific patient is actually a good candidate. Stem cell therapy generates significant interest, and patients who have exhausted conventional options often arrive at a clinic hoping it will be the answer. In many cases it may genuinely help. In other cases the patient’s condition has progressed beyond what biological therapy can meaningfully address, or other factors make the expected benefit low enough that a different path makes more sense. Understanding what makes someone a stronger or weaker candidate helps patients have more productive clinical conversations and helps set expectations that reflect reality.

Why Candidacy Is Not Universal

What Makes Someone a Strong vs. Poor Candidate

Stem cell therapy works through biological mechanisms that depend on the tissue environment. Cells injected into a joint or soft tissue target need a substrate to work with. They signal other cells, reduce local inflammation, and may support the regeneration of damaged tissue. But these effects are not unlimited, and they are not independent of the condition of the receiving tissue.

A strong candidate typically has a tissue environment that still has enough structural integrity to respond to biological signals. There is cartilage, tendon, or other target tissue present, even if damaged. The patient’s overall health allows their cells to be collected, processed, and re-injected with adequate quality and yield. Their condition has not responded to conservative care, so the clinical picture supports moving to a more intensive intervention. And their expectations align with what the evidence actually supports.

A weaker candidate may have a joint that has lost nearly all cartilage surface, leaving bone in contact with bone. In this environment, there is no tissue substrate for regenerative biology to work with. Or the patient may have uncontrolled metabolic disease that impairs cell function. Or they may have active infection, autoimmune flare, or be on medications that suppress the biological response regenerative therapy depends on.

Why Reputable Clinics Turn Patients Away

A pattern that distinguishes high-quality regenerative clinics from marketing-driven ones is whether the physician is willing to decline patients who are not appropriate candidates. Turning a patient away when they are not likely to benefit is clinically responsible. It protects the patient from an expensive procedure that carries procedural risk but limited expected benefit. It also protects the physician’s clinical credibility.

When a clinic accepts every patient who presents regardless of their clinical picture, that is a signal worth paying attention to. Regenerative therapy is not appropriate for every condition, every stage of disease, or every patient profile. A physician who explains the limits of their approach and recommends alternatives when appropriate is demonstrating integrity that matters for every aspect of care, not just candidacy decisions.

Factors That Support Candidacy

Degree of Tissue Damage: The Spectrum

The most important structural factor in candidacy is how much damage the target tissue has sustained. For osteoarthritis, the most widely used grading system is the Kellgren-Lawrence (KL) classification, which radiographically assesses joint space narrowing, osteophyte formation, subchondral sclerosis, and bone contour changes on a scale from 0 to 4.

KL Grade 1 reflects doubtful narrowing of joint space and possible osteophytic lipping. KL Grade 2 reflects definite osteophytes and possible narrowing of joint space. KL Grade 3 reflects moderate multiple osteophytes, definite narrowing of joint space, and some sclerosis. KL Grade 4 reflects large osteophytes, marked narrowing of joint space, severe sclerosis, and definite deformity of bone contour.

Clinical research, including systematic reviews published between 2019 and 2024, generally supports KL Grade 1 through 3 as the range where stem cell therapy for osteoarthritis tends to produce meaningful patient-reported improvements in pain and function. KL Grade 3 is a transition zone. Some patients at Grade 3 retain enough cartilage to respond well. Others, particularly those at the severe end of Grade 3 approaching Grade 4 changes, may have a tissue environment that limits biological response. MRI evaluation provides additional detail beyond plain X-ray, showing cartilage thickness, bone marrow edema, meniscus integrity, and synovial changes that help the physician make a more precise assessment.

For soft tissue conditions, MRI grading of tendon or labral pathology similarly guides candidacy. Partial thickness tendon tears and chronic tendon degeneration without complete structural disruption are different clinical situations than complete full-thickness tears. The nature and degree of the lesion matters.

Overall Health and Biological Baseline

The cells used in autologous stem cell therapy come from the patient. This means the quality and yield of those cells depend directly on the patient’s biological health at the time of collection. Several systemic factors affect cell quality and the clinical response to treatment.

Metabolic health is meaningful. Patients with well-controlled metabolic status generally have better cell yield and quality than those with poorly controlled chronic metabolic disease. Obesity does not automatically exclude a patient from consideration, but the distribution and quality of adipose tissue can affect harvest efficiency and cell characteristics. Physicians factor this into both the collection approach and the expected yield.

Smoking significantly impairs healing biology. Nicotine and other tobacco constituents reduce oxygen delivery to tissue, impair microcirculation, and suppress cellular repair mechanisms. Patients who smoke may have reduced response to regenerative therapy, and many physicians recommend cessation prior to treatment as a condition of candidacy or as strongly encouraged guidance.

Uncontrolled diabetes impairs both wound healing and cell function. Elevated blood glucose interferes with cellular repair signaling in ways that are well-documented in the surgical and wound healing literature. Patients with well-controlled diabetes may still be candidates, while those with significant glycemic dysregulation represent a more complex clinical situation.

Immunosuppressive medications present a specific concern. Some medications, including certain disease-modifying antirheumatic drugs and corticosteroids, suppress immune function in ways that may blunt the biological response that regenerative therapy depends on. Physicians evaluating patients on these medications must assess the timeline for stopping or adjusting them relative to treatment and the risks of doing so.

Age is a factor but not a disqualifier. Research suggests that younger patients may have higher cell yield and more robust biological response, but patients in their 60s, 70s, and beyond may still be appropriate candidates when other factors support it. Physician assessment integrates age with the full clinical picture rather than applying a rigid age cutoff.

Prior Treatments and Why They Matter

The treatment history preceding a regenerative consultation provides important clinical information. A patient who has tried physical therapy, anti-inflammatory medications, activity modification, bracing, and oral supplements and has not found adequate relief is a different clinical picture than one who has had minimal prior treatment.

Prior corticosteroid injections deserve specific attention. Corticosteroids suppress inflammation but may also suppress the local biological environment in ways that affect how regenerative therapy works. Most physicians recommend a minimum interval between the last corticosteroid injection and a regenerative procedure, commonly three months or longer, though the optimal interval is still a matter of clinical judgment and individual context.

Prior surgery in the treatment area can affect tissue anatomy and biology in ways that alter both candidacy and expected response. A patient who has had a previous meniscectomy has a different joint environment than one who has not. Prior ligament reconstruction, cartilage repair procedures, and joint replacement revisions all affect the anatomy that regenerative therapy would be working within.

Patients who have received prior regenerative treatment in the same area and have not responded provide a different kind of information. A non-response to a prior well-performed procedure raises the question of whether the tissue environment supports the biological response, and this context shapes the conversation about whether a repeat procedure is appropriate.

Conditions That Commonly Respond Well

Early to Moderate Osteoarthritis

Osteoarthritis affecting the knee, hip, shoulder, and ankle at KL Grade 1 through 3 represents the most studied and most commonly treated application of stem cell therapy in the musculoskeletal space. The rationale is straightforward: these are conditions where cartilage loss is real and progressive, where conventional treatments address symptoms but not the underlying tissue environment, and where the target tissue still has enough structure to potentially respond to biological signals.

Clinical evidence from systematic reviews published in 2023 and 2024 indicates that mesenchymal stem cell injections for early to moderate knee osteoarthritis are associated with meaningful improvements in patient-reported pain scores and functional outcomes at six to twelve months. Reviews covering 12 to 16 trials with hundreds of patients have generally found that patients with KL Grade 1 to 3 disease report reduced pain and improved function compared to baseline. Individual results vary, and the quality of the available evidence varies across studies, but the overall pattern from the current literature supports cautious optimism for this patient group.

Tendon and Soft Tissue Injuries

Tendon conditions represent a strong application for regenerative therapy because of a specific biological challenge: tendons are largely avascular structures. They have limited blood supply, which is one reason tendon injuries heal slowly and often incompletely. Regenerative therapies, including both PRP and stem cell injections, may help address this by introducing growth factors and cellular signals directly into tissue that lacks the natural biological resources that more vascular tissue has access to.

Clinical evidence and patient reports suggest that partial thickness rotator cuff tears, patellar tendinopathy, Achilles tendinopathy, plantar fasciitis, and lateral and medial epicondylitis (tennis and golfer’s elbow) may respond to regenerative intervention, particularly in patients who have undergone conservative care without adequate resolution. The evidence is stronger for some of these conditions than others. Lateral epicondylitis and Achilles tendinopathy have been studied in controlled trials, while evidence for other tendon conditions comes primarily from case series and observational studies.

Chronic tendon degeneration, sometimes called tendinosis to distinguish it from acute tendinitis, is a condition where the normal collagen architecture of the tendon has broken down over time. This is a tissue-level structural problem that physical therapy and anti-inflammatory approaches may not fully address. Regenerative therapy targets the tissue biology directly, which is why it is considered a meaningful option in carefully selected patients with chronic tendinosis.

Certain Neurological and Systemic Conditions

The evidence base for regenerative therapy in neurological applications is less developed than in musculoskeletal applications, and this distinction matters for honest candidacy conversations. Some patients with peripheral neuropathy, including diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy, have sought regenerative therapy. Research in this area is ongoing, and clinical evidence is still accumulating. Patients considering regenerative therapy for neurological symptoms should receive an explicit and honest discussion of what the current evidence supports and where significant uncertainty remains.

Candidacy assessment for neurological or systemic applications is appropriately more conservative than for musculoskeletal applications, both because the evidence base is earlier-stage and because the biological mechanisms of action are less well-characterized in these contexts. Physicians who apply the same candidacy standards to neurological applications as they do to musculoskeletal applications are not reflecting the difference in evidence depth between the two areas.

Conditions Where Stem Cell Therapy Is Less Appropriate

End-Stage Joint Damage

KL Grade 4 osteoarthritis, characterized by bone-on-bone contact and the near or complete absence of cartilage, represents the structural limit for regenerative therapy in joint disease. The biological rationale for stem cell therapy depends on the presence of tissue for cells to interact with. When cartilage is gone, the repair signaling mechanisms that regenerative therapy activates have no tissue substrate to work with.

Physicians who are honest about this limit will tell Grade 4 patients that regenerative therapy is unlikely to produce the structural improvement they are hoping for. Some patients with Grade 4 disease still ask whether there is benefit to pain reduction even without structural change, and some clinical reports suggest that anti-inflammatory effects from regenerative injections may offer temporary symptom relief even in advanced cases. However, the magnitude and durability of any benefit in this population is lower than in earlier-stage disease, and the conversation about surgical evaluation is typically more appropriate than the conversation about regenerative treatment.

An honest physician who sees a Grade 4 X-ray and still discusses total joint arthroplasty consultation alongside or instead of regenerative options is serving that patient’s interests. That is what ethical practice looks like in this context.

Active Infection or Certain Autoimmune States

Active systemic infection is a relative contraindication to regenerative procedures. The rationale is that infection anywhere in the body creates a systemic inflammatory state and an immune burden that may redirect biological resources away from the intended therapeutic response and may complicate the recovery period.

Active local infection in or around the target joint is an absolute contraindication. Introducing a biologically active cell product into an infected joint creates unacceptable risk of spreading infection, impairing the natural immune response, or converting a manageable infection into a serious one.

Patients with autoimmune conditions occupy a complex candidacy category. The condition and its current activity level, the medications used to manage it, and the specific treatment target all factor into the assessment. Some autoimmune patients may be appropriate candidates under certain conditions. Others may not. There is no simple rule that applies across all autoimmune presentations, and the evaluation requires physician judgment specific to the individual case.

When Surgery Is the Correct First Step

Several structural conditions are better addressed by surgery than by regenerative therapy, and recognizing this is as important as understanding when regenerative therapy is appropriate.

Complete ACL tears with resulting joint instability require reconstruction for functional stability. Regenerative therapy cannot restore the mechanical function of a completely torn ligament in the same way that surgical reconstruction can. A patient with an unstable knee from an ACL-deficient state and a plan to return to cutting and pivoting sports needs reconstruction, not injection.

Large meniscus tears that create a mechanical block to knee motion, causing locking or significant range of motion limitation, require surgical evaluation. The mechanical problem cannot be resolved through biological injection.

Complete rotator cuff tears that involve full-thickness disruption across a significant portion of the cuff may require surgical repair to restore shoulder function, particularly in active patients. Partial thickness tears and degenerative tearing without complete disruption represent a different clinical situation that may be appropriate for regenerative evaluation.

Nerve compression causing progressive motor weakness or significant sensory deficit from structural causes such as herniated disc or spinal stenosis requires decompression evaluation. Regenerative therapy does not address structural compression of neurological tissue.

The willingness of a regenerative medicine physician to refer patients for surgical evaluation when that is the correct path is one of the clearest indicators of clinical integrity in this space. Patients benefit from physicians who know what they can address and what they cannot, and who make referrals when referrals are appropriate.

Sources

Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. This content is not a substitute for consultation with a qualified, licensed healthcare provider. Regenerative medicine procedures vary in outcomes based on individual health status, condition severity, and other clinical factors. No specific results are guaranteed. Consult a board-certified physician to determine whether any treatment discussed here is appropriate for your situation.